Investors may believe the company's moderate P/S ratio and b...
Investors may believe the company's moderate P/S ratio and benign revenue growth rate might not outperform the industry. Continuation of recent medium-term revenue trends could risk a share price decline, endangering shareholders' investments.
Subdued Growth No Barrier To Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) Price
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment